Johnson & Johnson

Arsenal Forms Digital, AI, and Data Analytics Group

Retrieved on: 
Thursday, March 14, 2024
Organization, Growth, Digital, Arsenal, Patient, Artificial intelligence, AI, Medicine, The Advisory Board Company, Johnson & Johnson, Safety, Health, Pharmaceutical industry

NEW YORK, March 14, 2024 /PRNewswire/ -- Arsenal Capital Partners ("Arsenal"), a leading private equity firm specializing in building technology-rich, market-leading healthcare and industrial growth companies, today announced the formation of its Digital, AI, and Data Analytics Group.

Key Points: 
  • NEW YORK, March 14, 2024 /PRNewswire/ -- Arsenal Capital Partners ("Arsenal"), a leading private equity firm specializing in building technology-rich, market-leading healthcare and industrial growth companies, today announced the formation of its Digital, AI, and Data Analytics Group.
  • The group will leverage next-generation innovation and emerging technologies in predictive analytics, artificial intelligence, and digital automation to enhance the development, delivery, and administration of products and services for Arsenal's healthcare portfolio companies.
  • The group will be comprised initially of Dr. Dimitris Agrafiotis, Scott Blanchette, and Nick Reding, three experienced professionals who bring differentiated talents, capabilities, and experiences to Arsenal.
  • Arsenal Operating Partner, Dave Spaight, observed, "Arsenal is committed to driving technology enablement and transformation within healthcare.

Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer

Retrieved on: 
Thursday, March 14, 2024
Johnson & Johnson, Seed, Philosophy, Patient, Neoplasm, Factorization of polynomials, Publication, Therapy, Immune system, Antigen

The financing was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. – with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.

Key Points: 
  • The financing was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. – with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
  • Asgard Therapeutics' approach enables the transformation of cancer cells into immune cells to induce a broad immune response specific to the patient's own tumors.
  • The approach uses direct cell reprogramming to transform tumor cells into a sub-type of dendritic cell which present tumor antigens to the immune system.
  • "Asgard promises to leapfrog a core challenge in immuno-oncology – the heterogeneity of solid tumors – through the first pan-tumoral cell reprogramming approach.

Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer

Retrieved on: 
Thursday, March 14, 2024
Johnson & Johnson, Seed, Philosophy, Patient, Neoplasm, Factorization of polynomials, Publication, Therapy, Immune system, Antigen

The financing was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. – with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.

Key Points: 
  • The financing was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. – with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
  • Asgard Therapeutics' approach enables the transformation of cancer cells into immune cells to induce a broad immune response specific to the patient's own tumors.
  • The approach uses direct cell reprogramming to transform tumor cells into a sub-type of dendritic cell which present tumor antigens to the immune system.
  • "Asgard promises to leapfrog a core challenge in immuno-oncology – the heterogeneity of solid tumors – through the first pan-tumoral cell reprogramming approach.

FOOT LOCKER, INC. NAMES CINDY CARLISLE CHIEF HUMAN RESOURCES OFFICER

Retrieved on: 
Wednesday, March 13, 2024
Roche, Foot Locker, Executive, Culture, Stryker Corporation, Human resources, Growth, Johnson & Johnson, Management

NEW YORK, March 13, 2024 /PRNewswire/ -- Foot Locker, Inc. (NYSE: FL) today announced that Cindy Carlisle has assumed the role of Executive Vice President and Chief Human Resources Officer.

Key Points: 
  • Carlisle brings over 24 years of leadership experience to her role at Foot Locker, Inc.
    NEW YORK, March 13, 2024 /PRNewswire/ -- Foot Locker, Inc. (NYSE: FL) today announced that Cindy Carlisle has assumed the role of Executive Vice President and Chief Human Resources Officer.
  • As Chief Human Resources Officer of Foot Locker, Inc., Carlisle will be responsible for developing and executing the Company's global human resources strategy in support of the Company's Lace Up Plan, a transformation designed to drive the organization's next phase of growth and create value for all stakeholders.
  • "I am deeply honored to join Foot Locker, Inc. at this critical moment of transformation and growth," said Carlisle.
  • Carlisle joins Foot Locker, Inc. from Stryker Corporation, where she served as Group Vice President of Human Resources.

4A'S NAMES CATHY CHAN BUTLER AS EXECUTIVE VICE PRESIDENT OF TALENT, EQUITY & LEARNING SOLUTIONS

Retrieved on: 
Tuesday, March 12, 2024
BIPOC, American Express, Certification, Adweek, HuffPost, IKEA, Learning, The New York Times, Partnership, Equity, 4A, Woman, Advertising, Johnson & Johnson, API, Management

In this role, Cathy will lead the 4A's Foundation, Learning Institute and HR/Talent Solutions practice while also joining the Executive Leadership Team.

Key Points: 
  • In this role, Cathy will lead the 4A's Foundation, Learning Institute and HR/Talent Solutions practice while also joining the Executive Leadership Team.
  • "We are thrilled to welcome Cathy as our new head of Talent, Equity & Learning Solutions at this critical juncture when attracting, retaining and developing talent remains a priority for our members," said Marla Kaplowitz, President and CEO of the 4A's.
  • "Cathy is an incredible talent and is going to channel her extensive experience leading agencies and her passion for advancing talent to serve our 4A's member community."
  • The 4A's unique relationship with agencies and agency leaders offers an elevated scale of opportunity to drive change and help advance the perspective on talent," said Cathy Chan Butler.

U.S. 1st Latino Tech Payroll Startup Trez.co, Announces Advisory Board of Industry Giants and C-Suite Executives As It Opens Its Scaling Seed Round

Retrieved on: 
Monday, March 11, 2024
CIO, Waste management, Growth, Mentorship, Box, GSK, JPMorgan Chase, Organizational founder, Central Waqf Council, UnitedHealth Group, Johnson & Johnson, Cisco, Stanford University, CMO, ADP, Corporation

SAN FRANCISCO, March 11, 2024 /PRNewswire/ --

Key Points: 
  • Trez.co, the first U.S. Latino payroll platform company in the United States, is proud to announce its Board of Advisors.
  • This initiative underscores Trez.co's commitment to driving national economic growth through customer first payroll, benefits, and financial solutions tailored to the unique needs of Latino businesses and employees.
  • "Trez is the successful outcome of conversations initiated from LBAN (latino business action network) at Stanford University.
  • Maria Eugenia brings vast corporate governance experience as she has led several boards as the chairman of the board.

Neptune Software: 'Environmental Supply Chains - You Don't Need to Sacrifice Profitability to Act Sustainably'

Retrieved on: 
Monday, March 11, 2024
Printing, U.S. Sugar, CertainTeed, Carbon, Neptune, Paper, App Store (iOS/iPadOS), Transaction, Carbon footprint, Transport, Johnson & Johnson, Online shopping

"Fully modernizing your company's supply chain with mobile and digital processes is a critical step in reducing carbon emissions, but you don't need to sacrifice profitability to act sustainably," said Neptune Software CEO Andreas Grydeland Sulejewski.

Key Points: 
  • "Fully modernizing your company's supply chain with mobile and digital processes is a critical step in reducing carbon emissions, but you don't need to sacrifice profitability to act sustainably," said Neptune Software CEO Andreas Grydeland Sulejewski.
  • Many companies' global supply chains still rely on paper to operate.
  • That, in turn, helps supply chains run more efficiently by optimizing deliveries.
  • Retailers using Neptune are also creating applications that allow customers to learn the sustainability rating of products they may be considering purchasing.

EQS-News: DOUGLAS Group sets price range for its IPO

Retrieved on: 
Wednesday, March 13, 2024
CFO, Jefferies, Supervisory board, Deutsche Bank, Competition Commission, FMCG, GfK, Investment, Research, Management, Growth, Johnson & Johnson, Primary shares, UBS, Sale, Calendar, Beauty, Frankfurt Stock Exchange, IPO, CVC Capital Partners, Federal Financial Supervisory Authority, LBBW, Organization, Economics, Goldman Sachs, RBI, Citigroup, CVC, BNP Paribas, UniCredit, Intesa Sanpaolo, Security (finance)

The price range implies a total market capitalization of between 2.8 billion euro and 3.1 billion euro.

Key Points: 
  • The price range implies a total market capitalization of between 2.8 billion euro and 3.1 billion euro.
  • The German Federal Financial Supervisory Authority (BaFin) approved the securities prospectus for the public offer in Germany and listing of DOUGLAS today.
  • With our strong business model and successful growth strategy, the DOUGLAS Group is optimally positioned in a very attractive market.
  • Through Management Equity Programs, the members of the Executive Board as well as current and former managers of the DOUGLAS Group have indirectly invested in the company.

Ambrx Shareholders Approve Acquisition by Johnson & Johnson

Retrieved on: 
Wednesday, March 6, 2024
SAN, Special, Cancer, Johnson & Johnson, ADC, Protein engineering, Security (finance)

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders.

Key Points: 
  • SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders.
  • As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction.
  • Daniel J. O’Connor, Chief Executive Officer of Ambrx, said, “We want to thank our shareholders for their strong support of this transaction.
  • Ambrx now expects to complete the transaction on or about March 7, 2024, subject to the satisfaction of customary closing conditions.

ACTG Presents Study at CROI Demonstrating Efficacy of Long-Acting Injectable Treatment Among People Who Had Previously Been Unable to Maintain Viral Suppression on Daily Oral Medication

Retrieved on: 
Wednesday, March 6, 2024
Infection, Chair, Bangladesh Technical Education Board, Mental health, Injection (medicine), University of Alabama, Rilpivirine, Fungal infection, NIAID, Arm, CROI, PWH, Quality of life, ACTG, Johnson & Johnson, Data monitoring committee, Conference, Health, University, ART, UM1, Male, DSMB, ViiV Healthcare, HIV, Failure, University of North Carolina, Vaccine

“ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

Key Points: 
  • “ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.
  • Participants received incentives and support to adhere to their daily oral medication to first achieve viral suppression and if successful, they were randomized to either receive long-acting injectable treatment every four weeks or continue taking daily oral medication.
  • The long-acting injectable treatment was more effective than the daily oral medication at maintaining virologic suppression and avoiding treatment-related discontinuation.
  • Twenty-eight participants receiving the long-acting injectable treatment experienced regimen failure (defined as virologic failure or treatment discontinuation), compared to 47 receiving daily oral medication.